| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Aminotetrahydroethylene 4-P-PDOT (10 mM) in the absence or presence of melatonin did not alter the levels of cyclic AMP induced by forskolin in CHO-mt1 cells. On the other hand, 4-P-PDOT is an agonist that, in the presence of -MT2 cells in CHO, results in concentration-dependent suppression of cyclic AMP induced by forskolin, with a pEC50 value of 8.72 and an actual activity of 0.86 [1]. Test for Cell Viability [5] Cell
|
|---|---|
| ln Vivo |
The administration of 4-P-PDOT (0.5-1.0 mg/kg; intravenous; klotho mutation) markedly counteracted the antioxidant benefits mediated by melatonin. and dramatically undid the variations in these GSH-related parameter values. 4-P-PDOT therapy dramatically improved the memory function of klotho mutants treated with melatonin. 4-P-PDOT can also control Nrf2, the expression of phosphorylated ERK in the klotho mutant hippocampal region, which is known as melatonin-mediated signal attenuation.
|
| Cell Assay |
Cell Viability Assay[5] Cell
Cell Types: HT-29 and HeLa cells. Tested Concentrations: 50 µM Incubation Duration: 30 minutes Experimental Results: Negligible effect on melatonin-induced cell viability. |
| Animal Protocol |
Animal/Disease Models: treating Klotho mutant mice with melatonin [2]
Doses: 0.5 mg/ kg or 1.0 mg/kg. Route of Administration: intravenous (iv) (iv)injection. Experimental Results: Dramatically reversed nuclear translocation, Nrf2 DNA binding activity and diminished GCL mRNA expression [2]. Antioxidant effects mediated by melatonin. Dramatically reversed the changes in the levels of these GSH-related parameters. Dramatically reverses memory function in melatonin-treated klotho mutant mice. |
| References |
|
| Additional Infomation |
N-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide is a member of tetralins.
|
| Molecular Formula |
C19H21NO
|
|---|---|
| Molecular Weight |
279.383
|
| Exact Mass |
279.162
|
| CAS # |
134865-74-0
|
| PubChem CID |
3976006
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.11g/cm3
|
| Boiling Point |
480.1ºC at 760 mmHg
|
| Flash Point |
292ºC
|
| Vapour Pressure |
2.22E-09mmHg at 25°C
|
| Index of Refraction |
1.595
|
| LogP |
4.05
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
348
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RCYLUNPFECYGDW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H21NO/c1-2-19(21)20-16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,2,12-13H2,1H3,(H,20,21)
|
| Chemical Name |
cis-N-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
|
| Synonyms |
4P-PDOT 4PPDOTAH-0244-P-PDOT 4-phenyl-2- propionamidotetralin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~41.67 mg/mL (~149.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.17 mg/mL (14.93 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 4.17 mg/mL (14.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5794 mL | 17.8968 mL | 35.7935 mL | |
| 5 mM | 0.7159 mL | 3.5794 mL | 7.1587 mL | |
| 10 mM | 0.3579 mL | 1.7897 mL | 3.5794 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
